- call +1-201-465-4211
- email sales@mrinsights.biz
The Aedes aegypti mosquito is responsible for transmitting the dengue virus (DENV). The virus that causes dengue belongs to the Flavivirus genus of the Flaviviridae family. Dengue fever resembles influenza and affects adults, children, as well as infants, but it is rarely fatal. However, dengue hemorrhagic fever is a potentially fatal complication because of multiple factors such as fluid accumulation, severe bleeding, organ impairment, or plasma leaking.
Scope of the Report:
This report focuses on the Dengue Vaccine in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
With the increasing population density and global warming, there is a rapid growth in the prevalence of dengue, especially in the tropical and subtropical regions across the world. According to the National Institute of Health, approximately 0.05 to 0.2 billion cases of dengue infections are reported annually and the mortality rate due to dengue was above 20,000. The report has identified the rapid growth in disease incidences as one of the primary factors that will fuel the growth of the dengue vaccine market in the coming years. The prevalence of dengue is present in more than 125 countries across the world and the rising prevalence of dengue will drive the market during the forecast period.
The dengue vaccine market is marginally concentrated due to the presence and dominance of the established players. Several companies are investing in R&D to develop more advanced products and expand their product portfolio. Several organizations are merging for research and making enormous efforts to develop vaccines that can challenge the Sanofi Pasteur's exclusivity in the dengue treatment market. Moreover, several organizations are making huge investments in R&D to develop novel treatment options.
The Americas will be the major revenue contributor to the dengue vaccine market owing to the increasing incidences of dengue cases. The dengue treatment market in the Americas will profit from the bilateral program, Indo-U.S. Vaccine Action Program (VAP), which is concentrated on activities related to immunization and vaccine-related research.
The worldwide market for Dengue Vaccine is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
GlaxoSmithKline
Merck Sharp & Dohme
Sanofi
Takeda Pharmaceuticals
GeneOne Life Sciences
Medigen Biologics
Panacea Biotec
Sun Pharmaceutical
U.S NIH
Vabiotec
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
CYD-TDV
DENVax or TAK-003
TetraVax-DV
TDENV PIV
V180
DNA vaccines
Market Segment by Applications, can be divided into
Government institutions
Hospitals
NGOs
There are 15 Chapters to deeply display the global Dengue Vaccine market.
Chapter 1, to describe Dengue Vaccine Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Dengue Vaccine, with sales, revenue, and price of Dengue Vaccine, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Dengue Vaccine, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Dengue Vaccine market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Dengue Vaccine sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Dengue Vaccine Introduction
1.2 Market Analysis by Type
1.2.1 CYD-TDV
1.2.2 DENVax or TAK-003
1.2.3 TetraVax-DV
1.2.4 TDENV PIV
1.2.5 V180
1.2.6 DNA vaccines
1.3 Market Analysis by Applications
1.3.1 Government institutions
1.3.2 Hospitals
1.3.3 NGOs
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 GlaxoSmithKline
2.1.1 Business Overview
2.1.2 Dengue Vaccine Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 GlaxoSmithKline Dengue Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Merck Sharp & Dohme
2.2.1 Business Overview
2.2.2 Dengue Vaccine Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Merck Sharp & Dohme Dengue Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Sanofi
2.3.1 Business Overview
2.3.2 Dengue Vaccine Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Sanofi Dengue Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Takeda Pharmaceuticals
2.4.1 Business Overview
2.4.2 Dengue Vaccine Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Takeda Pharmaceuticals Dengue Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 GeneOne Life Sciences
2.5.1 Business Overview
2.5.2 Dengue Vaccine Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 GeneOne Life Sciences Dengue Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Medigen Biologics
2.6.1 Business Overview
2.6.2 Dengue Vaccine Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Medigen Biologics Dengue Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Panacea Biotec
2.7.1 Business Overview
2.7.2 Dengue Vaccine Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Panacea Biotec Dengue Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Sun Pharmaceutical
2.8.1 Business Overview
2.8.2 Dengue Vaccine Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Sun Pharmaceutical Dengue Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 U.S NIH
2.9.1 Business Overview
2.9.2 Dengue Vaccine Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 U.S NIH Dengue Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Vabiotec
2.10.1 Business Overview
2.10.2 Dengue Vaccine Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Vabiotec Dengue Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Dengue Vaccine Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Dengue Vaccine Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Dengue Vaccine Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Dengue Vaccine Manufacturer Market Share in 2017
3.3.2 Top 6 Dengue Vaccine Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Dengue Vaccine Market Analysis by Regions
4.1 Global Dengue Vaccine Sales, Revenue and Market Share by Regions
4.1.1 Global Dengue Vaccine Sales and Market Share by Regions (2013-2018)
4.1.2 Global Dengue Vaccine Revenue and Market Share by Regions (2013-2018)
4.2 North America Dengue Vaccine Sales and Growth Rate (2013-2018)
4.3 Europe Dengue Vaccine Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Dengue Vaccine Sales and Growth Rate (2013-2018)
4.5 South America Dengue Vaccine Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Dengue Vaccine Sales and Growth Rate (2013-2018)
5 North America Dengue Vaccine by Countries
5.1 North America Dengue Vaccine Sales, Revenue and Market Share by Countries
5.1.1 North America Dengue Vaccine Sales and Market Share by Countries (2013-2018)
5.1.2 North America Dengue Vaccine Revenue and Market Share by Countries (2013-2018)
5.2 United States Dengue Vaccine Sales and Growth Rate (2013-2018)
5.3 Canada Dengue Vaccine Sales and Growth Rate (2013-2018)
5.4 Mexico Dengue Vaccine Sales and Growth Rate (2013-2018)
6 Europe Dengue Vaccine by Countries
6.1 Europe Dengue Vaccine Sales, Revenue and Market Share by Countries
6.1.1 Europe Dengue Vaccine Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Dengue Vaccine Revenue and Market Share by Countries (2013-2018)
6.2 Germany Dengue Vaccine Sales and Growth Rate (2013-2018)
6.3 UK Dengue Vaccine Sales and Growth Rate (2013-2018)
6.4 France Dengue Vaccine Sales and Growth Rate (2013-2018)
6.5 Russia Dengue Vaccine Sales and Growth Rate (2013-2018)
6.6 Italy Dengue Vaccine Sales and Growth Rate (2013-2018)
7 Asia-Pacific Dengue Vaccine by Countries
7.1 Asia-Pacific Dengue Vaccine Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Dengue Vaccine Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Dengue Vaccine Revenue and Market Share by Countries (2013-2018)
7.2 China Dengue Vaccine Sales and Growth Rate (2013-2018)
7.3 Japan Dengue Vaccine Sales and Growth Rate (2013-2018)
7.4 Korea Dengue Vaccine Sales and Growth Rate (2013-2018)
7.5 India Dengue Vaccine Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Dengue Vaccine Sales and Growth Rate (2013-2018)
8 South America Dengue Vaccine by Countries
8.1 South America Dengue Vaccine Sales, Revenue and Market Share by Countries
8.1.1 South America Dengue Vaccine Sales and Market Share by Countries (2013-2018)
8.1.2 South America Dengue Vaccine Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Dengue Vaccine Sales and Growth Rate (2013-2018)
8.3 Argentina Dengue Vaccine Sales and Growth Rate (2013-2018)
8.4 Colombia Dengue Vaccine Sales and Growth Rate (2013-2018)
9 Middle East and Africa Dengue Vaccine by Countries
9.1 Middle East and Africa Dengue Vaccine Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Dengue Vaccine Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Dengue Vaccine Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Dengue Vaccine Sales and Growth Rate (2013-2018)
9.3 UAE Dengue Vaccine Sales and Growth Rate (2013-2018)
9.4 Egypt Dengue Vaccine Sales and Growth Rate (2013-2018)
9.5 Nigeria Dengue Vaccine Sales and Growth Rate (2013-2018)
9.6 South Africa Dengue Vaccine Sales and Growth Rate (2013-2018)
10 Global Dengue Vaccine Market Segment by Type
10.1 Global Dengue Vaccine Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Dengue Vaccine Sales and Market Share by Type (2013-2018)
10.1.2 Global Dengue Vaccine Revenue and Market Share by Type (2013-2018)
10.2 CYD-TDV Sales Growth and Price
10.2.1 Global CYD-TDV Sales Growth (2013-2018)
10.2.2 Global CYD-TDV Price (2013-2018)
10.3 DENVax or TAK-003 Sales Growth and Price
10.3.1 Global DENVax or TAK-003 Sales Growth (2013-2018)
10.3.2 Global DENVax or TAK-003 Price (2013-2018)
10.4 TetraVax-DV Sales Growth and Price
10.4.1 Global TetraVax-DV Sales Growth (2013-2018)
10.4.2 Global TetraVax-DV Price (2013-2018)
10.5 TDENV PIV Sales Growth and Price
10.5.1 Global TDENV PIV Sales Growth (2013-2018)
10.5.2 Global TDENV PIV Price (2013-2018)
10.6 V180 Sales Growth and Price
10.6.1 Global V180 Sales Growth (2013-2018)
10.6.2 Global V180 Price (2013-2018)
10.7 DNA vaccines Sales Growth and Price
10.7.1 Global DNA vaccines Sales Growth (2013-2018)
10.7.2 Global DNA vaccines Price (2013-2018)
11 Global Dengue Vaccine Market Segment by Application
11.1 Global Dengue Vaccine Sales Market Share by Application (2013-2018)
11.2 Government institutions Sales Growth (2013-2018)
11.3 Hospitals Sales Growth (2013-2018)
11.4 NGOs Sales Growth (2013-2018)
12 Dengue Vaccine Market Forecast (2018-2023)
12.1 Global Dengue Vaccine Sales, Revenue and Growth Rate (2018-2023)
12.2 Dengue Vaccine Market Forecast by Regions (2018-2023)
12.2.1 North America Dengue Vaccine Market Forecast (2018-2023)
12.2.2 Europe Dengue Vaccine Market Forecast (2018-2023)
12.2.3 Asia-Pacific Dengue Vaccine Market Forecast (2018-2023)
12.2.4 South America Dengue Vaccine Market Forecast (2018-2023)
12.2.5 Middle East and Africa Dengue Vaccine Market Forecast (2018-2023)
12.3 Dengue Vaccine Market Forecast by Type (2018-2023)
12.3.1 Global Dengue Vaccine Sales Forecast by Type (2018-2023)
12.3.2 Global Dengue Vaccine Market Share Forecast by Type (2018-2023)
12.4 Dengue Vaccine Market Forecast by Application (2018-2023)
12.4.1 Global Dengue Vaccine Sales Forecast by Application (2018-2023)
12.4.2 Global Dengue Vaccine Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Dengue Vaccine Picture
Table Product Specifications of Dengue Vaccine
Figure Global Sales Market Share of Dengue Vaccine by Types in 2017
Table Dengue V
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
